HOOKIPA Pharma Announces $21.25 Million Equity Investment from Gilead Sciences
December 21, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
Gilead purchased 15 million newly issued shares of common stock at a price of $1.4167 per shareFollowing the close of the transaction on December 20, 2023, Gilead holds 19.4% of HOOKIPA’s outstanding...
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus
November 20, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
Novel arenaviral therapeutic vaccine, developed in collaboration with Gilead Sciences, Inc. (‘Gilead’), to be evaluated as a potential curative regimen for human immunodeficiency virus (HIV)Phase 1...
HOOKIPA Pharma Reports Third Quarter 2023 Financial Results and Recent Business Highlights
November 09, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong...
HOOKIPA Pharma Presents Positive Biomarker and Translational Data on HB-200 Monotherapy at Society for Immunotherapy of Cancer 2023
November 03, 2023 12:01 ET
|
HOOKIPA Pharma Inc.
HB-200 monotherapy induced a robust increase in circulating tumor-specific CD8+ T cells in all evaluable Phase 1 patients with heavily pretreated HPV16+ head and neck cancer T cell responses were...
HOOKIPA Pharma to Report Third Quarter 2023 Financial Results and Recent Business Highlights on November 9, 2023
November 02, 2023 16:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Nov. 02, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...
HOOKIPA Pharma Presents Additional Preliminary Phase 2 Data on HB-200 in Combination with Pembrolizumab as First-Line Treatment in Patients with HPV16+ Head and Neck Cancers at European Society for Medical Oncology Congress 2023
October 22, 2023 06:01 ET
|
HOOKIPA Pharma Inc.
42 percent objective response rate (ORR) was observed among 19 evaluable patients with recurrent/metastatic head and neck cancer in the first-line setting—doubling historical ORR reported with...
HOOKIPA Pharma announces publication of preclinical data of hepatitis B virus (HBV) therapeutic vaccine developed in collaboration with Gilead Sciences
October 18, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
HB-400, a novel arenaviral therapeutic vaccine, generates robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical settingA Gilead-led Phase 1 clinical trial to...
HOOKIPA Announces Executive Leadership Change
September 13, 2023 08:45 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 12, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus...
HOOKIPA Pharma to participate in upcoming investor conferences in September
September 06, 2023 07:01 ET
|
HOOKIPA Pharma Inc.
NEW YORK and VIENNA, Austria, Sept. 06, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary...